Clinical Scorecard: Long-term effectiveness and kidney safety of SGLT2 inhibitors in heart failure patients with advanced chronic kidney disease (stage 4): a retrospective cohort study using propensity score matching

At a Glance

Key Highlights

• SGLT2i associated with 38% relative risk reduction in heart failure hospitalization or cardiovascular death.
• No significant difference in major adverse kidney events between SGLT2i and control groups.
• SGLT2i showed a shallower annualized eGFR decline compared to standard care.

Guideline-Based Recommendations

Diagnosis

• Evaluate heart failure in patients with advanced CKD using eGFR criteria.

Management

• Consider SGLT2 inhibitors for heart failure patients with advanced CKD despite previous exclusion in trials.

Monitoring & Follow-up

• Monitor renal function and signs of acute kidney injury during SGLT2i therapy.

Risks

• Be aware of potential acute kidney injury and eGFR decline upon initiation of SGLT2i.

Patient & Prescribing Data

Patients with heart failure and advanced CKD (Stage 4).

SGLT2i may provide cardiovascular benefits without significant renal safety concerns.

Clinical Best Practices

• Utilize propensity score matching to minimize confounding in observational studies.
• Adhere to ethical guidelines in research involving vulnerable populations.

Related Resources & Content

• KDIGO Classification
• STROBE Guidelines